Press Release: Newcleo Plc Reports First Half 2026 Financial and Operational Results

Dow Jones
Oct 02

First Half 2026 and Subsequent Commercial and Operational Highlights

   -- Completed business combination with NewHold Investment Corp III ("SPAC") 
      on September 21, 2026 (the "Business Combination"); newcleo's ordinary 
      shares and warrants commenced trading on the Nasdaq Global Select Market 
      on September 22, 2026 under the symbols "NWCL" and "NWCLW," respectively 
 
   -- The Business Combination generated gross proceeds of approximately $247 
      million, consisting of approximately $31 million released from the SPAC's 
      trust account and $216 million from the PIPE financing 
 
   -- Raised approximately $18.7 million in additional financing unrelated to 
      the Business Combination since May 2026, bringing total funds raised 
      since newcleo's founding to over $1 billion 
 
   -- Installed the main vessel and turbine for its PRECURSOR non-nuclear 10 
      MWt demonstration reactor at the ENEA Brasimone Research Center outside 
      Bologna, Italy; completion of construction for PRECURSOR is expected by 
      the end of 2026, with at-scale validation of systems to commence 
      thereafter 
 
   -- In partnership with Oklo, selected by the U.S. Department of Energy for 
      advanced negotiations under the Surplus Plutonium Utilization Program 
 
   -- Submitted Regulatory Engagement Plans to the U.S. Nuclear Regulatory 
      Commission for the Company's LFR-AS-200 lead-cooled fast reactor and its 
      planned U.S. mixed-oxide (MOX) fuel manufacturing facility 
 
   -- Received notice of an overall opinion of satisfactory compliance from the 
      French Nuclear Safety and Radiation Protection Authority for the proposed 
      safety features for the Company's planned MOX fuel manufacturing facility 
      in France 
 
   -- Announced the acquisition, subject to customary closing conditions, of 
      Bonifait Pesage, a French manufacturer of nuclear-grade scales and 
      precision industrial weighing equipment, augmenting the Company's 
      vertically integrated capabilities 
 
   -- Announced the appointment of Jeffrey Lyash, a nuclear industry veteran 
      and former head of the Tennessee Valley Authority, as Chairman of the 
      Board of Directors 
 
   -- Announced the appointment of William D. Magwood as Vice-Chairman of 
      newcleo's Board of Directors, effective January 1, 2027 
 
   -- Announced the hiring of Dustin Greenwood as Vice President of U.S. 
      Operations and Travis Chapman as Director of U.S. Regulatory Affairs and 
      Licensing, strengthening the Company's growing U.S. team 
 
   -- Announced a partnership with SHINE to assess and jointly pursue 
      opportunities relating to nuclear fuel recycling in the United States and 
      European Union 
 
   -- On September 10, 2026, newcleo held an Analyst and Investor Day, a 
      recording of which is available on newcleo's website 

First Half 2026 Financial Highlights

   -- Generated Revenue from Products and Services of approximately EUR19.4 
      million, an increase of approximately 46% over First Half 2025 
 
   -- Reported Net Loss of approximately EUR82.0 million, an increase of 
      approximately 10% over First Half 2025 
 
   -- Reported Tangible Capital Expenditures of EUR25.3 million, an increase of 
      37% over First Half 2025 
 
   -- Reported Selling, General & Administrative expenses of EUR59.2 million, 
      an approximately 21% increase over First Half 2025 
 
   -- Cash & Cash Equivalents as of June 30, 2026 stood at EUR66.5 million 
 
   -- Total ordinary shares outstanding as of the closing date of the Business 
      Combination stood at 281,534,950 
 
   -- As of September 30, 2026, preliminary, unaudited Cash & Cash Equivalents 
      for the Company stood at approximately EUR233 million 

LONDON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- newcleo plc (Nasdaq: NWCL) ("newcleo" or the "Company"), a pioneer in advanced modular reactor ("AMR") technology and nuclear fuel manufacturing, today announced its operational and financial results for the six months ended June 30, 2026.

"Becoming a public company is a defining milestone for newcleo, and I want to thank every member of our team for the work that brought us to this point and to reporting our first results as a public company," said Stefano Buono, Founder and CEO of newcleo. "Access to the public markets strengthens our ability to execute on our mission to deliver a credible, near-term path to advanced nuclear deployment and to close the nuclear fuel cycle. The disciplined engineering, licensing, and partnership work carried out by our more than 900 employees across Europe and the United States will continue to drive newcleo's progress, and I am excited to work with this incredible team every day.

"Importantly, newcleo is moving quickly down the path to both technical validation and regulatory approval for our facilities. The installation of the main vessel for PRECURSOR, our 10 MWt non-nuclear demonstration reactor at Brasimone, is a development milestone for the LFR technology ahead of planned commercial deployment. Completion of construction for PRECURSOR, which is expected by the end of 2026, and beginning the process of reactor system validation, are the next critical steps in qualifying the technology that will lead to the deployment of our LFR-200 reactor.

"In parallel, pre-licensing for our reactor and MOX fuel facilities in France, Slovakia and the United States, including our ongoing engagement with the U.S. Nuclear Regulatory Commission, has moved forward. Our U.S. growth is a particular focus: our work toward siting at Savannah River, and the broader policy support for nuclear expansion in the U.S., position newcleo to play a meaningful role in meeting U.S. energy demand, including from AI infrastructure. We look forward to updating investors on our progress."

Commercial & Operational Events

On May 26, newcleo was selected by the U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program. The program aims to make designated surplus plutonium material available to industry participants and enable the conversion of those materials into fuel for advanced nuclear reactors, subject to U.S. security, safeguards and material accountability requirements. newcleo's selection, in partnership with Oklo, continues the companies' strategic partnership as they work together to develop advanced fuel fabrication infrastructure in the U.S.

On June 16, 2026, the Company announced a partnership with SHINE to collaborate on advancing innovative technologies for the recycling of used nuclear fuel. Under the agreement, the parties will assess how SHINE could supply newcleo with reprocessed materials from the used nuclear fuel of traditional reactors to manufacture MOX fuel, and how SHINE could recycle spent fuel from newcleo's reactors. The parties also intend to jointly pursue U.S. federal funding opportunities and explore additional opportunities for collaboration across both the U.S. and European Union, where spent fuel stockpiles represent a growing strategic priority to support energy independence.

On June 30, 2026, newcleo announced its entry into an agreement to acquire Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial weighing equipment with a strong customer base in the French nuclear ecosystem. Bonifait Pesage manufactures, installs, calibrates, and maintains weighing equipment, while also providing technical support. Since 2017, the company has held key certifications for the maintenance and verification of weighing systems used in ionizing-radiation environments. The acquisition forms part of newcleo's vertical integration strategy, pursued since 2023, and is expected to close in the fourth quarter of 2026, subject to customary closing conditions. It is intended to bring critical manufacturing capabilities in-house, secure access to nuclear-grade weighing equipment required for planned MOX fuel manufacturing facilities, reduce supply-chain risk and support equipment customization.

Also subsequent to the first half, newcleo progressed work on the PRECURSOR non-nuclear demonstration reactor with the installation of the main vessel and turbine at ENEA's Brasimone facility located outside of Bologna, Italy. The 10 MWt non-nuclear demonstration reactor, which is scheduled for completion at the end of 2026, is intended to provide the Company with a fully integrated, representative operating and power generating environment for the Company's planned commercial reactors. Experimental data obtained through the operation of PRECURSOR is expected to inform the Company's licensing processes on both sides of the Atlantic, including safety computations, system performance analysis and materials development.

"In the first half of 2026, newcleo continued moving our operations forward, continuing to convert planning into reality," said Elisabeth Rizzotti, Co-Founder, Deputy-CEO and COO of newcleo. "Our OTHELLO test loop is operating, PRECURSOR is under active construction at Brasimone with major components manufactured and installed by our own vertically integrated subsidiaries, which gives us direct control over cost, schedule, and quality across the supply chain rather than relying on third parties for critical systems. At the same time, our work with trusted partners continues to translate into concrete engineering and commercial work. Each of these efforts, testing, building, manufacturing, and partnering, reflects the same discipline: turning our technology roadmap into physical progress on the ground."

Regulatory Progress

Subsequent to the end of the first half, on July 17, newcleo announced that it had received from the French Nuclear Safety and Radiation Protection Authority ("ASNR") an overall satisfactory evaluation for the proposed safety features of its planned MOX fuel manufacturing facility in France. The review by the ASNR offers practical feedback to continue developing the facility's safety features ahead of a license application and valuable experience to support the licensing process in the U.S. The Company is also progressing through a similar regulatory process for its lead-cooled fast reactor design and is currently awaiting the opinion of the ASNR on the proposed safety features of that design.

On August 6, newcleo announced the submission of a Regulatory Engagement Plan (REP) to the U.S. Nuclear Regulatory Commission (NRC) for its planned mixed-oxide (MOX) fuel fabrication facility, to be located in Aiken, South Carolina. The submission of a REP for the MOX facility followed the submission on July 14 to the NRC of a REP for the Company's LFR-AS-200 reactor. The submitted REPs set out the proposed framework for newcleo's pre-application engagement with NRC staff in support of the future licensing of both the MOX facility and the LFR-AS-200 lead-cooled fast reactor. The REPs provide an overview of the Company's proposed licensing approach and an indicative schedule for technical submissions and interactions with the NRC.

Hiring of Key Personnel

On June 11, newcleo announced the hiring of Dustin Greenwood as Vice President of U.S. Operations and Travis Chapman as Director of U.S. Regulatory Affairs and Licensing to direct and support the Company's growing presence in the U.S. Both Greenwood and Chapman are experienced nuclear professionals, having worked in the U.S. Navy's nuclear propulsion program, as well as at leading companies developing advanced reactor and nuclear fuel projects. Dustin Greenwood will lead the development of newcleo's U.S. operational footprint and oversee execution of the Company's American projects. He will focus on establishing operational capabilities, building strategic partnerships and supporting delivery of the Company's U.S. deployment roadmap. Travis Chapman will lead newcleo's U.S. licensing, permitting and regulatory engagement strategy, overseeing the Company's interactions with federal regulators and supporting the licensing pathway for newcleo's advanced reactor and fuel technologies.

On September 9, the Company announced the appointment of Jeffrey Lyash to serve as Chairman of the Board of Directors. Lyash brings more than 40 years of experience spanning engineering, procurement, construction, and operations across the power generation, transmission, and distribution sectors. He most recently served as President and Chief Executive Officer of the Tennessee Valley Authority (TVA), the largest public utility in the United States, where he oversaw generation from coal, nuclear, hydroelectric, natural gas, and renewable sources while driving significant improvements in operating efficiency. Prior to TVA, Lyash served as President and CEO of Ontario Power Generation, where he was responsible for $45 billion in assets and an 11,000-person workforce. He also served as President of Chicago Bridge & Iron's Power Business Unit, leading engineering, procurement, and construction for multi-billion-dollar generation projects globally.

On September 30, the Company announced the appointment of William D. Magwood as Vice-Chairman of newcleo's Board of Directors, effective January 1, 2027. Magwood has spent the past decade as Director-General of the OECD Nuclear Energy Agency $(NEA)$, where he works directly with the nuclear regulators and energy ministries of NEA's member countries. Magwood will step down from his position at the NEA at the end of 2026 prior to assuming his position as newcleo's Vice-Chairman.

First Half Financial Summary

 
(Amounts in thousands)                        For the Six Months Ended 
                                           ------------------------------ 
                                             6/30/2026       6/30/2025 
                                                           -------------- 
Revenue from Products and Services          EUR    19,429   EUR    13,347 
Gross Profit                                        6,130           4,154 
Other Income                                        6,554           4,763 
Net Loss                                           81,981          74,293 
Capital Expenditures                               26,970          19,000 
Cash & Cash Equivalents (end of period)            66,540         131,896 
 
 

Revenue from Products and Services increased by approximately EUR6.1 million, or approximately 46%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase was attributable to manufacturing and installation of equipment and spare parts for third parties as well as consultancy services.

Other Income increased by approximately EUR1.8 million, or 38%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase was comprised of grant income and an increase in research and development tax credits, both generated in France and Italy, as well as an increase in other income relating to a one-time project outside the Company's core operations.

Gross Profit increased by approximately EUR2.0 million, or 48%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in Gross Profit was due to increases in revenue outpacing increases in costs for the First Half 2026.

Net loss increased by approximately EUR7.7 million, or 10%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to higher non-cash share-based payment expense as well as third-party related expenses.

Tangible capital expenditures were approximately EUR25.3 million for the six months ended June 30, 2026, compared to approximately EUR18.5 million for the six months ended June 30, 2025. The increase was due to investments in technology and testing experimental facilities.

Selling, General & Administrative expenses were EUR59.2 million for the six months ended June 30, 2026, compared to approximately EUR48.9 million for the six months ended June 30, 2025. The increase in SG&A expense was primarily due to increases in share-based payment expense, and increases in other staff costs related to transaction incentives payable on completion.

The Company had Cash & Cash Equivalents available of EUR66.5 million as of June 30, 2026, compared to EUR105.3 million as of December 31, 2025 and EUR131.9 million as of June 30, 2025.

About newcleo

newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo's technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit http://www.newcleo.com

Contacts

For Investors and Media:

newcleo@icrinc.com

media@newcleo.com

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding newcleo's development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo's demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo's ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo's expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management's intentions, beliefs, or expectations with respect to newcleo's future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as "anticipate," "believe, " "continue," "could," "develop," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would," and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the SEC. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking

statements, each of which is made only as of the date of this press release.

 
             Condensed Consolidated Statements of Profit or Loss 
                  and Other Comprehensive Income (Unaudited) 
 
                                                            For the six months 
                                                              ended June 30 
                      For the six months ended June 30,            2026 
                           2026                2025 
                                                               Convenience 
                        (in thousands of euros unless        translation into 
                              otherwise stated)                US dollars* 
Revenue from 
 Products and 
 Services                       19,429              13,347              22,149 
Cost of sales                 (13,299)             (9,193)            (15,161) 
Gross profit                     6,130               4,154               6,988 
 
Other income                     6,554               4,763               7,472 
Research and 
 development 
 expenses                     (34,629)            (35,450)            (39,477) 
Selling, General 
 and 
 Administrative 
 expenses                     (59,170)            (48,932)            (67,454) 
Operating loss                (81,115)            (75,465)            (92,471) 
 
Loss on disposal 
 of assets                         (9)                 (3)                (10) 
Finance income                     353               1,581                 402 
Finance costs                  (1,448)               (991)             (1,650) 
Share of loss of 
 associates                       (83)                   -                (95) 
Loss before income 
 tax                          (82,302)            (74,878)            (93,824) 
 
Income tax benefit                 321                 585                 366 
Net loss                      (81,981)            (74,293)            (93,458) 
 
Other 
comprehensive 
income (loss) 
Items that may be 
subsequently 
reclassified to 
profit or loss 
Currency 
 translation 
 differences                       198               (144)                 226 
Other 
 comprehensive 
 income (loss), 
 net of tax                        198               (144)                 226 
 
Total 
 comprehensive 
 loss                         (81,783)            (74,437)            (93,232) 
 
Net loss 
attributable to: 
Owners of newcleo 
 plc                          (81,981)            (74,293)            (93,458) 
Non-controlling 
interest                             -                   -                   - 
 
Total 
comprehensive loss 
attributable to: 
Owners of newcleo 
 plc                          (81,783)            (74,437)            (93,232) 
Non-controlling 
interest                             -                   -                   - 
Net loss per share 
for loss 
attributable to 
the ordinary 
equity holders: 
Basic and diluted 
 loss per share                 (0.16)              (0.16)              (0.18) 
 
 

*Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14).

Note: EPS for the period ended June 30, 2026 is calculated based on the number of shares before the share consolidation. Following the closing of the Business Combination, it would be restated to $(0.34).

 
           Condensed Consolidated Statements of Financial Position 
                                  (Unaudited) 
 
 
                                              December 31, 
                           June 30, 2026          2025         June 30, 2026 
                                                                Convenience 
                            (in thousands of euros unless     translation into 
                                  otherwise stated)             US dollars* 
ASSETS 
NON-CURRENT ASSETS 
Goodwill                            37,281            37,281            42,500 
Intangible assets, net              42,760            43,054            48,746 
Property, plant and 
 equipment, net                    115,999            93,436           132,239 
Right-of-use asset                  17,665            18,521            20,138 
Investments                             76                75                87 
Investments in 
 associates                         31,553            31,635            35,970 
Other long-term 
 receivables                        34,871            35,207            39,753 
Deferred tax assets                  3,059             2,176             3,487 
TOTAL NON-CURRENT 
 ASSETS                            283,264           261,385           322,920 
 
CURRENT ASSETS 
Inventories                          4,843             5,057             5,521 
Short-term investments               2,335             2,291             2,662 
Trade receivable, 
 contract and other 
 assets, net                        77,768            62,314            88,656 
Cash and cash 
 equivalents                        66,540           105,270            75,856 
TOTAL CURRENT ASSETS               151,486           174,932           172,695 
TOTAL ASSETS                       434,750           436,317           495,615 
 
NON-CURRENT LIABILITIES 
Provisions                           4,094             4,170             4,667 
Other liabilities                    8,932             9,305            10,182 
Lease liabilities                   14,667            15,537            16,720 
Borrowings                          15,929            16,306            18,159 
Deferred tax 
 liabilities                         4,430             4,244             5,050 
TOTAL NON-CURRENT 
 LIABILITIES                        48,052            49,562            54,778 
 
CURRENT LIABILITIES 
Provisions                             378               186               431 
Trade and other 
 payables                           60,055            83,808            68,463 
Lease liabilities                    3,545             3,250             4,041 
Borrowings                           2,497             2,583             2,847 
TOTAL CURRENT 
 LIABILITIES                        66,475            89,827            75,782 
TOTAL LIABILITIES                  114,527           139,389           130,560 
 
EQUITY 
Share capital                        5,046             4,739             5,752 
Share premium                       23,378           562,904            26,652 
Other reserves                      57,067            51,383            65,057 
Retained earnings 
 (accumulated 
 deficits)                         234,695         (324,123)           267,552 
                         -----------------  ----------------  ---------------- 
Equity attributable to 
 owners of newcleo plc             320,186           294,903           365,013 
Non-controlling 
 interests                              37             2,025                42 
TOTAL EQUITY                       320,223           296,928           365,055 
TOTAL EQUITY AND 
 LIABILITIES                       434,750           436,317           495,615 
 

*Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14).

 
            Condensed Consolidated Cash Flow Statement (Unaudited) 
 
                                                           For the six months 
                       For the six months ended June 30    ended June 30 2026 
                            2026              2025 
                                                              Convenience 
                                                            translation into 
                           (in thousands of euros)                US$* 
Cash flows from 
operating 
activities 
Net loss                      (81,981)          (74,293)              (93,458) 
Adjustments to 
reconcile net loss 
to net cash flows: 
-------------------- 
   Loss from 
    associates                      83                 -                    95 
   Finance income                 (30)           (1,476)                  (34) 
   Finance costs                 1,131               830                 1,289 
   Income tax 
    benefit                      (321)             (585)                 (366) 
   Depreciation of 
    property, plant 
    and equipment 
    and right-of-use 
    assets, 
    amortization 
    intangible 
    assets and 
    provisions                   8,286             7,397                 9,446 
   Share-based 
    payment expense             21,010             4,975                23,951 
   Loss on disposals                 9                 4                    10 
   Other revenues 
    and expenses 
    without effect 
    on cash flow                     3                 5                     3 
Changes in working 
capital:                                                                     - 
-------------------- 
   Decrease in 
    inventory                      214                94                   244 
   (Increase) in 
    trade 
    receivables, 
    contract and 
    other assets              (15,217)           (6,781)              (17,347) 
   Increase 
    (decrease) in 
    trade and other 
    payables                    13,077           (2,428)                14,908 
   Income taxes 
    received                        49                25                    56 
Net cash flows used 
 in operating 
 activities                   (53,687)          (72,233)              (61,203) 
 
Cash flows from 
investing 
activities 
Acquisition of 
 intangible assets             (1,642)             (458)               (1,872) 
Purchase of 
 property, plant and 
 equipment                    (25,328)          (18,542)              (28,874) 
Proceeds from 
 maturities of 
 short-term 
 investments                         -               997                     - 
Purchase of 
 short-term 
 investments                      (41)             (160)                  (47) 
Interest received 
 from short-term 
 investments                        30             1,477                    34 
Decrease (increase) 
 in loans and 
 deposits made                       4               (2)                     5 
Proceeds from sale 
 of tangible and 
 intangible assets                  10                 5                    12 
Net cash flows used 
 in investing 
 activities                   (26,967)          (16,683)              (30,742) 
 
Cash flows from 
financing 
activities 
Proceeds from issues 
 of shares                      45,121                 -                51,438 
Proceeds from issue 
 of shares to 
 non-controlling 
 shareholders                        -            31,637                     - 
Repayments of 
 borrowings and 
 lease liabilities             (2,129)           (2,535)               (2,427) 
Interest expenses 
 including interest 
 on lease                      (1,131)             (800)               (1,289) 
Net cash flows from 
 financing 
 activities                     41,861            28,302                47,722 
 
Net decrease in cash 
 and cash 
 equivalents                  (38,793)          (60,614)              (44,223) 
 
Cash and cash 
 equivalents at the 
 beginning of the 
 period                        105,270           192,714               120,008 
Effect of foreign 
 exchange rate 
 changes                            63             (204)                    71 
Cash and cash 
 equivalents at the 
 end of the period              66,540           131,896                75,856 
 
 

*Convenience translation into US$ in thousands

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10